Leadership Team

The executive team at NDA has the privilege of leading an organization of unmatched experience in the drug development disciplines. With backgrounds from entrepreneurship, large and small research organisations and the regulatory agencies they work together to continually grow NDA and expand our capabilities in line with the evolving needs of our industry.

 

Leadership Team

Johan Strömquist

CEO

Read more

Johan Strömquist

CEO

Has worked as CEO and entrepreneur in the IT service industry. Has supported for the pharmaceutical industry since the 1990s. Focuses on developing NDA as the undisputed global leader of strategic development advice, taking into account all critical commercial and regulatory considerations to successfully bring good medicines to patients in need.

Laurie Smaldone Alsup

CSO/CMO

Read more

Laurie Smaldone Alsup

CSO/CMO

Laurie has over 25 years of global leadership experience in the pharmaceutical and biotechnology industries in drug development, regulatory strategy and regulatory approvals across all major therapeutic areas. She has led the development and commercialization of drugs for oncology, HIV/AIDS, cardiovascular, metabolics, immunology, infectious diseases, neuroscience, dermatology, inflammatory and immune-based diseases.

Laurie has led numerous multidisciplinary teams in over 50 US FDA and European EMA proceedings, including preparations.

Kurt Stoeckli

President of Advisory Board

Read more

Kurt Stoeckli

President of Advisory Board

Seasoned healthcare executive with extensive industry experience and track record in the area of bio-pharmaceutical R&D strategy and operational management. Kurt joined NDA in April 2020, when he took over leadership of NDA’s advisory board.

Kurt brings extensive business acumen range from pre-clinical, clinical stages to the submission and approval of assets; he is familiar with scientific, medical, ethical, technical, regulatory and commercial success factors in life sciences.

Dr Thomas Lönngren

Strategic Advisor

Read more

Dr Thomas Lönngren

Strategic Advisor

Thomas joined NDA as a strategic advisor in 2011 advising the company’s management and its clients on management and drug development strategies. He applies his skills to a broad range of regulatory and management areas and has successfully helped clients interact with regulatory agencies throughout the stages of development and during regulatory review.

Thomas was the Executive Director of the European Medicines Agency (EMA). He established the agency from a small unknown agency in 2001 to a world-renowned regulatory agency in 2011 and was responsible for all its operations. He previously served with the Swedish Medical Products Agency (MPA) as Director of Operations (1978-93) and Deputy Director-General, (Jan 93 – Dec 00).

Contact Us

Your drug development needs are unique

Contact us to learn how our experts can support you to meet all regulatory, quality and safety requirements and ensure the best path to approval.

Let's Bring Medicines to the World